Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type 2 Diabetes, Shift-work Disorder
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study will compare the effects of a whey protein supplement or a placebo consumed before the evening meal on health outcomes in night shift workers.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Prevention Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: whey protein — Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.
  • Dietary Supplement: Placebo — Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.

Primary Outcomes

  • Glycaemic response (12 days (3 hours meal test))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-04-27
Completion: 2026-07-31
Eligibility
Age: 35 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Adelaide
Principal Investigators:
  • Amy T Hutchison, PhD (PRINCIPAL_INVESTIGATOR) - University of Adelaide
Contact Information
Study Contact:
Amy Hutchison, PhD
8128 4862
amy.hutchison@adelaide.edu.au
Leonie Heilbronn, PhD
8128 4838
leonie.heilbronn@adelaide.edu.au
Amy T Hutchison, PhD
+61 8128 4862
amy.hutchison@adelaide.edu.au
University of Adelaide
Interventions
  • Dietary Supplement: whey protein — Protein drink containing 30g whey protein isolate powder (dissolved in water) consumed 1-1.5 hr prior to their main evening meal every day for 12 days, No other advice will be given.
  • Dietary Supplement: Placebo — Energy-matched mixed-nutrient placebo drink consumed 1-1.5 hr prior to their main evening meal every day for 12 days. No other advice will be given.
Study Locations (1 sites)
University of Adelaide, Adelaide, South Australia Australia
Eligibility Criteria
Inclusion Criteria: * Female * Night shift workers (with a minimum of 6 months in their current shift work schedule) * 35-65 years * BMI 28.0-35.0 kg/m2; waist circumference \> 80cm * Weight stable in the past 6 months Exclusion Criteria: * Those working standard day time hours only, or those who work less than three to four night shifts per fortnight on average * Personal history and/or diagnosis of: diabetes, cancer, major psychiatric disorders, liver disease, gastro-intestinal surgery or disease (including malabsorption), eating disorders, anaemia, insomnia or cardiovascular disease, and/or any other condition deemed unstable by the study physician * Taking medications known to alter body composition or metabolism, including (but not limited to): any medication used to lower blood glucose or antidiabetic medications (metformin, sulfonylureas, Glucagon-like peptide-1 (GLP-1) analogues \[i.e. exenatide\], thiazolidinediones or DPP-IV inhibitors \[i.e. 'gliptins'\]), medications affecting weight, appetite or gut motility (i.e. diuretics, domperidone, cisapride, orlistat, phentermine, topiramate) * Participants who are taking stable doses (i.e. \> 12 months) of androgenic medications (i.e. testosterone) or SSRI's will not be excluded. Personal history/diagnosis (self-reported) of diabetes (type 1 or 2), major psychiatric disorders (schizophrenia, major depressive disorder, bipolar disorder, eating disorders), gastrointestinal disorders, haematological disorders (i.e. thalassemia, iron-deficiency anaemia) insomnia, or any other medical condition, deemed unstable by the study physician * Pregnant, planning a pregnancy or breastfeeding * Those who have lost or gained \>5% of body weight in the last 6 months * Those who consume four or more standard drinks on a single occasion at a 'daily or almost daily' occurrence * current smokers of cigarettes/marijuana/e-cigarettes/vaporisers * unable to comprehend the study protocol (i.e. due to English language or cognitive difficulties)
Conditions Blood Pressure, Hypertension
Phase EARLY_PHASE1
Enrollment 46
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of our study is to understand the extent to which the blood vessels are affected by glucose and fat (lipids) in lean healthy adults and if these changes in the blood vessels contribute to the development of high blood pressure.

Design

Study type: Interventional Phases: Early Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Drug: Dextrose 20 % in 500 ML Injection — Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
  • Drug: Intralipid — Intralipid ® 20% will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, Intralipid ® 20% will be administered via antecubital vein at 0.75 mL/min for 2 hours Increases in circulating markers of oxidative stress peak within 2 hours of Intralipid ® 20% infusion in healthy adults (42). An initial heparin bolus of 1000 UL followed by 200 U/hr infusion will be included to activate endothelial lipoprotein lipase and accelerate hydrolysis of fatty acids.
  • Drug: Saline — Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.
  • Drug: Ascorbic acid — (ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a "drip-infusion" of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant.

Primary Outcomes

  • Efficacy of Infusion of Ascorbic Acid (Baseline)
  • Efficacy of Infusion of Ascorbic Acid (30 minutes)
  • Efficacy of Infusion of Ascorbic Acid (60 minutes)
  • Efficacy of Infusion of Ascorbic Acid (90 minutes)
  • Efficacy of Infusion of Ascorbic Acid (120 minutes)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2022-05-09
Completion: 2027-08-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 46 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Kansas Medical Center
Principal Investigators:
  • Seth W. W Holwerda, PhD (PRINCIPAL_INVESTIGATOR) - University of Kansas Medical Center
Contact Information
Study Contact:
Seth W Holwerda, PhD
9729223230
sholwerda@kumc.edu
Davina A Clonch
9132266009
shoggirl@gmail.com
Seth W. W Holwerda
9729223230
sholwerda@kumc.edu
University of Kansas Medical Center
Interventions
  • Drug: Dextrose 20 % in 500 ML Injection — Dextrose (20% intravenous solution) will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, dextrose will be administered via antecubital vein at a standard rate of 4 mg/kg/min for 2 hours.
  • Drug: Intralipid — Intralipid ® 20% will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. After fasting for at least 8 hours, Intralipid ® 20% will be administered via antecubital vein at 0.75 mL/min for 2 hours Increases in circulating markers of oxidative stress peak within 2 hours of Intralipid ® 20% infusion in healthy adults (42). An initial heparin bolus of 1000 UL followed by 200 U/hr infusion will be included to activate endothelial lipoprotein lipase and accelerate hydrolysis of fatty acids.
  • Drug: Saline — Saline will be obtained from the Investigational Pharmacy located in the KU Clinical Research Center where studies take place. Will be administered via antecubital vein at 75 to 150 mL/hour for 2 hours.
  • Drug: Ascorbic acid — (ASCOR) will be obtained from the KU Investigational Pharmacy located in the KU Clinical Research Center where studies will take place. A priming bolus of 0.06 g ascorbic acid/kg fat free mass (FFM) dissolved in 100 mL of saline will be infused intravenously at 5 mL/min for 20 minutes, followed immediately by a "drip-infusion" of 0.02 g/kg FFM dissolved in 30 mL of saline administered over 2 hours at 0.5 mL/min. The KU Investigational Pharmacy will randomize ascorbic acid or placebo (saline) for each participant.
Study Locations (1 sites)
University of Kansas Medical Center, Kansas City, Kansas 66103 United States
Eligibility Criteria
Inclusion Criteria: * Lean: BMI \< 25 kg/m * Normal insulin sensitivity: (calculation based on fasting glucose and insulin concentrations in blood) * Middle-aged: 18-79 years * Blood pressure: \< 140 (systolic) and \< 90 mmHg (diastolic * Weight stable (+/- 5 lbs) for the previous 3 months * Participants must be willing and able to discontinue taking any vitamin C or E supplements or omega-3 fatty acids beginning 2 weeks prior. * Able and willing to provide written informed consent Exclusion Criteria: * Diabetes mellitus Type I or Type II: fasting glucose \< 126 mg/dL and/or HbA1c \< 6.5% * Current smoker or History of smoking in the past 3 months. * Hyperlipidemia: Fasting triglycerides \< 250 mg/dL * Hypertension: \>130/80 mmHg * History of heart disease (e.g., myocardial infarction, stent, heart attack, stroke, heart failure, valvular heart disease, cardiomyopathy) * History of vascular disease (e.g., bypass, stroke)
Conditions Rhinitis, Allergic, Rhinoconjunctivitis,...
Phase PHASE3
Enrollment 180
Locations 32 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to moderate asthma sensitized to grasses and olive

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Biological: 10,000 MG01 + 10,000 T517 — Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
  • Biological: 30,000 MG01 + 10,000 T517 — Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
  • Other: Placebo — The same solution and presentation as the active treatment, but without active ingredients

Primary Outcomes

  • CSMS: Combined Symptoms and Medication Score (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2021-06-14
Completion: 2027-01
Eligibility
Age: 12 Years and older
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Inmunotek S.L.
Principal Investigators:
  • Irán Sánchez (STUDY_CHAIR) - Private Site
Contact Information
Study Contact:
Miguel Casanovas
912908942
mcasanovas@inmunotek.com
Raquel Caballero
607600638
rcaballero@inmunotek.com
ANTONIO MORENO FERNÁNDEZ, MD
Cedt de Tarancón
Interventions
  • Biological: 10,000 MG01 + 10,000 T517 — Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
  • Biological: 30,000 MG01 + 10,000 T517 — Purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and Olea (Olea europaea), adsorbed on aluminum hydroxide. The other ingredients are: sodium chloride (0.9%), phenol (0.4%) and water for injections
  • Other: Placebo — The same solution and presentation as the active treatment, but without active ingredients
Study Locations (32 sites)
Cedt de Tarancón, Tarancón, Cuenca 16400 Spain
Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid 28805 Spain
Centro Médico Iza, Tres Cantos, Madrid 28760 Spain
Hospital Infanta Elena, Valdemoro, Madrid 28342 Spain
Hospital Clínico Universitario Virgen de Arrixaca, El Palmar, Murcia 30120 Spain
Private Practice, Albacete, 02003 Spain
Hospital Ntra. Sra. de Sonsoles, Ávila, 05004 Spain
Clinica Dermatologica Y Alergia, Badajoz, 06001 Spain
Hospital Quironsalud Clideba, Badajoz, 06011 Spain
Hospital Universitario Dexeus, Barcelona, 08028 Spain
Eligibility Criteria
Inclusion Criteria: 1. Subject who has signed the informed consent. 2. Subjects of both sexes aged between 12 and 65 years. 3. Subjects with confirmed clinical history of inhalational allergy (rhinitis and / or moderate-severe intermittent or persistent rhinoconjunctivitis according to the ARIA classification with or without intermittent or persistent controlled mild-moderate asthma according to the GEMA 5.0 classification caused by grass and olive allergy. The diagnosis of asthma will be valid from 12 months prior to signing the informed consent 4. Subjects with a positive prick test (higher papule diameter ≥ 5 mm) to a standardized extract of pollen from grasses (Phleum pratense, Holcus lanatus, Dactylis glomerata, Poa pratensis, Festuca elatior, Lolium perenne), or one of the components of the mixture and an olive extract. 5. Specific IgE (CAP or Immulite) against a mixture of grasses or against one of the components of the mixture of grasses, preferably Phleum pratense and olive or one of the molecular components of allergenic sources with a value \> 3,5 KU / L. 6. Women of childbearing age (from menarche) should submit a urine pregnancy test with a negative result at the time of joining the trial. 7. Women of childbearing potential, and men participating in the trial, should commit to using an appropriate method of contraception. Medically acceptable methods of contraception are intrauterine devices placed at least 3 months in advance, surgical sterilization (for example, tubal ligation), barrier methods, or the use of oral contraceptives. 8. Subjects capable of complying with the dosage regimen. 9. Subjects who have a smartphone to record symptoms and medication. 10. Subjects with a negative prick test to coestational pollens. In the case specific IgE is available, the result should be \<3,5 kU/L and without relevant symptomatology 11. Subjects with a negative prick test to other aeroallergens (dust mites, epitheliums and fungus). In the case specific IgE is available, the result should be \<3,5 kU/L and without relevant symptomatology Exclusion Criteria: 1. Subjects polysensitized to other aeroallergens with the exception of epithelia with occasional exposure and symptoms 2. Subjects polysensitized to other aeroallergens with the exception non-seasonal pollens with grasses and olive 3. Subjects who have received prior immunotherapy in the preceding 5 years to any aeroallergens. 4. Subjects in which immunotherapy may be subject to an absolute general contraindication according to the criteria of the Immunotherapy Committee of the Spanish Society of Allergy and Clinical Immunology and the European Allergy and Clinical Immunology Immunotherapy Subcommittee. 5. Subjects with severe or uncontrolled persistent asthma, with an FEV1 \<70% with respect to the reference value despite adequate pharmacological treatment at the time of inclusion in the trial. Likewise, subjects with intermittent or persistent rhinitis / rhinoconjunctivitis with severe symptoms in which the suspension of oral or systemic antihistamine treatment is contraindicated. 6. Subjects who have previously presented a serious secondary reaction during the performance of diagnostic skin tests using the prick test. 7. Subjects under treatment with ß-blockers. 8. Clinically unstable subjects at the time of enrolment in the trial (acute asthma exacerbation, respiratory infection, feverish process, acute urticaria, etc.). 9. Subjects with active chronic urticaria, severe dermographism, severe atopic dermatitis, sunburns, active psoriasis with lesions in areas where skin tests will be performed, or a history of hereditary angioedema. 10. Subjects who have any pathology in which the administration of adrenaline is contraindicated (hyperthyroidism, HT, heart disease, etc.). 11. Subjects with some other disease not related to moderate rhinoconjunctivitis or asthma, but of potential severity and that may interfere with treatment and follow-up (epilepsy, psychomotor disorder, uncontrolled diabetes, malformations, multiple operations, kidney disease,). 12. Subjects with autoimmune disease (thyroiditis, lupus, etc.), tumor diseases or with a diagnosis of immunodeficiencies. 13. Subject whose condition prevents him / her from offering cooperation and who has severe psychiatric disorders. 14. Subjects with a known allergy to other investigational drug components other than the allergen. 15. Subjects with diseases of the lower respiratory tract other than asthma such as emphysema or bronchiectasis. 16. Subjects who are direct relatives of the researchers. 17. Pregnant or lactating women.
Conditions Mild Asthma
Phase NA
Enrollment 148
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The objective of this study is to evaluate the pharmacodynamic (PD) bioequivalence (BE) of albuterol inhalers, test formulation: Albuterol Sulfate HFA inhalation aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation and reference formulation: ProAir HFA (albuterol sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg (equal to albuterol base 90 mcg) per actuation manufactured by two different manufacturers using methacholine bronchoprovocation challenge test in patients with stable mild asthma.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Other Masking/blinding: Triple

Interventions / Regimen

  • Drug: Albuterol Sulfate inhalation aerosol 108 mcg per actuation — equal to albuterol 90 mcg/puff, MDI
  • Drug: Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation — equal to albuterol 90 mcg/puff, MDI
  • Other: Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo — MDI
  • Other: Albuterol Sulfate inhalation Placebo — MDI
  • Other: Methacholine — Methacholine 100 mg/vial

Primary Outcomes

  • Post-dose PC20 Concentration (15 minutes post-dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-08-15
Completion: 2025-06
Eligibility
Age: 20 Years and older
Sex: ALL
Volunteers: false
Enrollment: 148 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Intech Biopharm Ltd.
Principal Investigators:
  • Pai-Chien Chou, MD, PhD (PRINCIPAL_INVESTIGATOR) - Taipei Medical University Hospital
Contact Information
Study Contact:
Jasmine Kuo
+886-2-7721-8877
jasmine.i199@intechbiopharm.com
Vaishal Sheth
Dr. Jivraj Mehta Smarak Health Foundation
Vaishal Sheth
Dr. Jivraj Mehta Smarak Health Foundation
Interventions
  • Drug: Albuterol Sulfate inhalation aerosol 108 mcg per actuation — equal to albuterol 90 mcg/puff, MDI
  • Drug: Proair HFA (Albuterol Sulfate) or FDA authorized generic: Albuterol Sulfate HFA (Teva Pharmaceutical USA, Inc.) Inhalation Aerosol 108 mcg per actuation — equal to albuterol 90 mcg/puff, MDI
  • Other: Proair HFA or FDA authorized generic: Albuterol Sulfate HFA Inhalation Placebo — MDI
  • Other: Albuterol Sulfate inhalation Placebo — MDI
  • Other: Methacholine — Methacholine 100 mg/vial
Study Locations (12 sites)
Dr. Jivraj Mehta Smarak Health Foundation, Ahmedabad, 38007 India
KLEs Dr Prabhakar Kore Hospital & MRC, Belagāve, 590010 India
NRS Medical College and Hospital, Kolkata, 700014 India
Medical College and Hospital, Kolkata, 700073 India
Aakash Healthcare Super Specialty Hospital, New Delhi, 110075 India
Pimpri Chinchwad Municipal Corporation Post Graduate Institute Yashwantrao Chavan Memorial Hospital, Pune, 411018 India
Kothrud Hospital, Pune, 411038 India
Ashirwad Hospital and Research Centre, Ulhasnagar, 421004 India
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City, 807 Taiwan
Tamshui Mackay Memorial Hospital, New Taipei City, 251 Taiwan
Eligibility Criteria
Inclusion Criteria: 1. Male, non-pregnant and non-lactating female subjects (20-65 years of age, inclusive). 2. A clinical diagnosis of mild asthma with historical documentation of the asthma diagnosis according to either: (1) the National Asthma Education and Prevention Program (NAEPP) guidelines (2007) or (2) the Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention (2020). 3. Stable mild asthma receiving the following required inhaled medications for at least 1 month prior to screening: Low doses of ICS alone, or in combination with SABA, used regularly with a stable regimen. 4. Forced Expiratory Volume in 1 second (FEV1) ≥ 80% of the local predicted normal value after withholding SABA ≥ 8 hours. 5. Airway responsiveness to methacholine demonstrated by a pre-albuterol-dose (baseline) PC20 ≤ 8 mg/mL. 6. Nonsmoker for at least 6 months prior to the study and a maximum smoking history of 5 pack-years (the equivalent of one pack per day for 5 years). 7. Provision of written informed consent. 8. Other than asthma, in general good health. 9. Body mass index (BMI) between 17 and 35 kg/m2 (inclusive). 10. Able to correctly use MDI inhalers. 11. Able to perform valid and reproducible pulmonary function tests including no evidence of spirometry effort-induced bronchoconstriction. 12. If the subject or subject's partner is of child-bearing potential, a medically acceptable form of contraception will be used for the duration of the study. Medically acceptable contraceptives include: (1) surgical sterilization, (2) Health Authority approved female hormonal contraceptives, (3) an intrauterine device (IUD), (4) condoms with spermicide, or (5) diaphragm with spermicide. Exclusion Criteria: 1. Evidence of conditions altering airway reactivity to methacholine, including upper or lower respiratory tract infections (e.g., pneumonia, viral bronchitis, allergic rhinitis, sinobronchitis, etc.) within 6 weeks before Screening. 2. Evidence of a baseline FEV1 \< 60% of the local predicted normal value or FEV1 \< 1.5 L. 3. History of seasonal asthma exacerbations, in which case the subject should be studied outside of the relevant allergen season. 4. History of cystic fibrosis, bronchiectasis, COPD, or other respiratory diseases including COPD, chronic bronchitis, emphysema, tuberculosis, pulmonary carcinoma, pulmonary fibrosis, pulmonary hypertension that, in the opinion of the Investigator, would compromise subject safety or interfere with the evaluations. 5. History of cardiovascular, hematological, renal, neurologic, hepatic, psychiatric, endocrine dysfunction, including ECG with evidence of ischemic heart diseases and significant arrhythmias. 6. Treatment in an emergency room or hospitalization for acute asthmatic symptoms within 3 months prior to screening. 7. Known intolerance or hypersensitivity to any component of the albuterol MDI, beta2 receptor-agonist drug, HFA, any related compounds or methacholine. 8. Need for daily oral corticosteroids within 3 months prior to screening. 9. Cardiac arrhythmia or 12-lead electrocardiogram (ECG) abnormalities, that in the opinion of the Investigator would compromise subject safety or interfere with the evaluations, or a QTc \> 440 ms for males and \> 460 ms for females using Fredericia formula. 10. Subjects receiving beta blocker via any route or who may require beta blockers during the study. 11. History of narrow angle glaucoma, convulsive disorders, hyperthyroidism, uncontrolled diabetes, paradoxical bronchospasm. 12. History of malignancies. 13. History of alcohol or drug abuse. 14. Eye, brain, thoracic, and abdominal surgeries within 3 months prior to screening. 15. Use of cromyolyn, leukotriene receptor antagonists (LTRA), nedocromil, zileuton, theophylline, or long-acting beta-agonists (LABA) within 1 month prior to screening. 16. History of receiving muscarinic beta2-agonists (MABAs), short-acting muscarinic antagonists (SAMAs), long-acting muscarinic antagonists (LAMAs), anti-IgE, anti-IL5/5R, anti-IL4R, high dose ICS, or systemic corticosteroid for treatment of asthma within 6 months prior to screening. 17. Known Human Immunodeficiency Virus (HIV)-positive status. 18. Participated in any interventional clinical trials within 1 month prior to screening. 19. Pregnancy or breast feeding.
Conditions Anatomic Stage 0 Breast Cancer AJCC v8, ...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial studies the effect of calorie reduction while undergoing stereotactic ablative radiation therapy in treating patients with breast cancer. Stereotactic ablative radiation therapy (sABR) is a highly focused radiation treatment that gives an intense dose of radiation concentrated on a tumor, while limiting the dose to the surrounding organ. Giving SABR before surgery may make the tumor smaller. Adding dietary restrictions in combination with radiation therapy may help increase local control and decrease the spread of the cancer to other places in the body. The purpose of this trial is to identify if there is a decrease in tumor tissue in patients undergoing caloric restriction during pre-operative SABR, compared to patients undergoing pre-operative SABR alone.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Best Practice — Given standard dietary recommendations
  • Radiation: Stereotactic Body Radiation Therapy — Undergo SABR
  • Procedure: Resection — Undergo surgical resection
  • Procedure: Sentinel Lymph Node Biopsy — Undergo sentinel lymph node biopsy
  • Other: Dietary Intervention — Undergo a caloric restriction diet
  • Other: Questionnaire Administration — Ancillary studies
  • Other: Quality-of-Life Assessment — Ancillary studies
  • Procedure: Mammography — Undergo mammography

Primary Outcomes

  • Percent reduction in cellularity of breast tumor (4-16 weeks, depending on the date of surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-08-23
Completion: 2028-11-01
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Thomas Jefferson University
Principal Investigators:
  • Nicole Simone, MD (PRINCIPAL_INVESTIGATOR) - Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Contact Information
Study Contact:
Nicole Simone, MD
215-955-8874
Nicole.Simone@jefferson.edu
Nicole Simone, MD
215-955-6702
Nicole.Simone@jefferson.edu
Thomas Jefferson University Hospital
Interventions
  • Other: Best Practice — Given standard dietary recommendations
  • Radiation: Stereotactic Body Radiation Therapy — Undergo SABR
  • Procedure: Resection — Undergo surgical resection
  • Procedure: Sentinel Lymph Node Biopsy — Undergo sentinel lymph node biopsy
  • Other: Dietary Intervention — Undergo a caloric restriction diet
Study Locations (1 sites)
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania 19107 United States
Eligibility Criteria
Inclusion Criteria: * • Patients with pathologically proven DCIS or invasive breast cancer histologies * Willing and able to provide informed consent * Willing and able to comply with study treatments including dietary intervention * Body mass index (BMI) \>= 21 at time of enrollment * Age \>= 40 years at time of consent \* Patients with triple negative breast cancer (TNBC) must be \>= 50 years of age at time of consent * Karnofsky performance status (KPS) score 70 - 100 * Tumor size =\< 3.0 cm * Gross disease within the breast must be unifocal \* Gross disease may be multifocal as long as the total extent of tumor, gross and microscopic, occupies a volume with greatest dimension =\< 3 cm * Patients with invasive disease are required to have clinical axillary staging including axillary ultrasound (US) that proves patient is clinically node negative or can be done by physical examination if the patient is over 70 * Patient is not being considered for preoperative chemotherapy * Must be English or Spanish speaking Exclusion Criteria: * Patient is clinically node positive: clinically suspicious axillary lymph node(s) by axillary US or exam unless biopsied and found to be negative * Patient has stage IV metastatic disease \* Patients with oligo-metastatic disease who are being treated with curative intent per the treating physician will not be excluded if all other eligibility criteria are met * Breast tumor size is \> 3.0 cm * Positive non-axillary sentinel nodes or evidence of suspicious supraclavicular, infraclavicular, or internal mammary nodes by imaging or physical exam, unless biopsied and found to be negative for tumor * Evidence by physical examination or mammography of other suspicious masses, densities, or microcalcifications in either breast, unless biopsied and found to be benign * Paget's disease of the nipple * Previous breast radiation on ipsilateral side * Any prior treatment with radiation therapy or chemotherapy for the current breast cancer diagnosis prior to registration * Patients with significant psychiatric illness that would preclude them from adhering to the protocol in the judgement of the treating clinician * BMI \< 21 at the time of study enrollment
Conditions Cannabis Use, Major Depressive Disorder,...
Phase NA
Enrollment 52
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore causal relationships are unclear. This study investigates the effects of cannabis abstinence over a 28-day period in patients with MDD with co-occurring CUD using a randomized controlled design, namely contingent reinforcement.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Contingency Reinforcement — Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
  • Behavioral: Non-Contingency Reinforcement — Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.

Primary Outcomes

  • Changes in Depressive Symptomology from Baseline to Week 4 ([Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)])
  • Changes in Anxious Symptomology from Baseline to Week 4 ([Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)])
  • Changes in Sleep Symptomology from Baseline to Week 4 ([Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)])
  • Changes in Anhedonia from Baseline to Week 4 ([Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)])
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-07-21
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 52 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre for Addiction and Mental Health
Principal Investigators:
  • Tony P George, MD., FRCPC (PRINCIPAL_INVESTIGATOR) - CAMH
Contact Information
Study Contact:
Maryam Sorkhou, HBSc
4165358501
maryam.sorkhou@mail.utoronto.ca
Tony P George, M.D.
Centre for Addiction and Mental Health
Interventions
  • Behavioral: Contingency Reinforcement — Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
  • Behavioral: Non-Contingency Reinforcement — Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
Study Locations (1 sites)
Centre for Addiction and Mental Health, Toronto, Ontario M5T 1R8 Canada
Eligibility Criteria
Inclusion Criteria: * All participants must be between the ages 18-55 * Meet SCID for DSM-5 diagnostic criteria for cannabis use disorder, moderate to severe * Meet SCID for DSM-5 diagnostic criteria for Major Depressive Disorder * Be an outpatient receiving a stable dose of antidepressant medication for at least three months (to ensure stability of depressive symptoms * Have a Hamilton Depression Rating Scale (HDRS-17) at baseline assessment in the range of 12-25.. * Have a Full-Scale IQ ≥ 80 as determined by the WTAR * Be a non-treatment seeking cannabis user * Evidence of sufficient motivation and effort as measured by a Test of Memory Malingering (TOMM) score ≥ 45. Exclusion Criteria: * Meets criteria for substance use disorder of alcohol or other illicit substances within the past 6 months (with the exception of cannabis, nicotine, or caffeine) * Positive urine screen for illicit substances other than cannabis, nicotine, or caffeine * Current suicidal or homicidal ideation * Psychotic disorder diagnosis (e.g. schizoaffective disorder, major depression with psychotic features) as determined by the SCID * Treatment seeking for cannabis use * Meet SCID for DSM-5 diagnostic criteria for Bipolar Disorder * Head Injury\> 5 minutes LOC * Exceed upper and lower cut-offs on HSRD-17 (See Inclusion Criteria)
Conditions Breast Cancer, Musculoskeletal Pain
Phase NA
Enrollment 30
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Chinese herbs can alleviates the side effects caused by conventional treatment in breast cancer patients and affects the syndrome element differentiation by altering the specific set of proteomes at specific time point of treatment.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Chinese Herbs — Chinese Herbs

Primary Outcomes

  • Feasibility of the study (Adherence) (Immediate post 1 week of Chinese Herbs intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-04-22
Completion: 2024-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Universiti Tunku Abdul Rahman
Principal Investigators:
  • Yang Mooi Lim (PRINCIPAL_INVESTIGATOR) - Universiti Tunku Abdul Rahman (UTAR)
Contact Information
Study Contact:
Chin Long Poo
0178853596
athrunjoe@gmail.com
King Keong Chung
0122027322
chungkk@tungshin.com.my
Tung Shin Hospital
Yang Mooi Lim
Tung Shin Hospital
Interventions
  • Dietary Supplement: Chinese Herbs — Chinese Herbs
Study Locations (1 sites)
Tung Shin Hospital, Bukit Bintang, Kuala Lumpur 55100 Malaysia
Eligibility Criteria
Inclusion Criteria: * Postmenopausal women as determined by cessation of menses for at least 1 year or FSH\>20 mIU/mL * Histology confirmed stage 2 to 3 hormone-receptor positive breast cancer patient * Currently taking letrozole for at least 1 month * Reported ongoing musculoskeletal pain or stiffness, which started or worsened after initiation of letrozole * Had a baseline average pain score over the past week on the Brief Pain Inventory Short Form (BPI-SF) of ≥4 points on a scale of 0 to 10. * Completed all indicated surgery, chemotherapy and radiation therapy * Agreed to take prescribed Chinese herbs * No evidence of distant metastasis * Follow-up for the duration of the study * No acute disease in the past month * Able to communicate to practitioner and interviewer * Willing to give informed consent Exclusion Criteria: * Pregnant or nursing woman or woman of childbearing potential without effective method of birth control. * Patients who default subsequent follow-up/ has irregular follow-up. * Patients who directly involved in other study at the same time. * History of non-compliance to medical regime and patients who are unwilling or unable to comply with the protocol. * Bedridden and/ or cancer metastasis to bone/ lung. * Concurrent infection requiring intravenous antibiotics * History of allergy to Chinese herbs * Had previously received Chinese herbs for their AI-induced musculoskeletal symptoms * Had received Chinese herbs within one month prior to study entry * Current use of steroids or narcotics for pain relief within the past 2 weeks * Subjects with acute onset of a chronic illness or with acute disease in the past month or had pre-existing chronic diseases * Patients with concomitant severe illness or metastatic disease (poorly controlled hypertension, hypothyroidism, diabetes mellitus, liver diseases, osteoarthritis, rheumatoid arthritis, gout or neuropathic arthropathy, autoimmune or inflammatory joint disease, bone fracture, stroke)
Conditions Breast Cancer Invasive, Early-stage Brea...
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired t-tests will be first used to compare TIL count in pre- and post-treatment specimens.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Azacitidine — 5-Azacitidine is a pyrimidine nucleoside analog in which nitrogen replaces carbon at position 5

Primary Outcomes

  • Change in tumor infiltrating lymphocytes (TILs) count in primary tumors from patients with high-risk early stage breast cancer following low-dose azacitidine therapy. (2 weeks from first dose of azacitidine)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-01-10
Completion: 2027-05
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Illinois at Chicago
Principal Investigators:
  • Vijayakrishna Krishnamurthy Gadi, MD, PhD (PRINCIPAL_INVESTIGATOR) - University of Illinois at Chicago
Contact Information
Study Contact:
VK Gadi, MD, PhD
312-996-1581
vkgadi@uic.edu
Michelle Karan, BS
224-563-7137
makaran2@uic.edu
VK Gadi, MD
312-996-1581
vkgadi@uic.edu
University of Illinois Cancer Center
Interventions
  • Drug: Azacitidine — 5-Azacitidine is a pyrimidine nucleoside analog in which nitrogen replaces carbon at position 5
Study Locations (1 sites)
University of Illinois Cancer Center, Chicago, Illinois 60612 United States
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years of age at time of consent 2. ECOG 0, 1, or 2 3. Histologically confirmed invasive breast carcinoma documented by biopsy. AJCC 8th edition clinical stage T1a-T3/N0-N1/M0 by physical exam or radiologic studies 4. Disease characteristics I. TNBC (Less than or equal to 10% of tumor cells staining for ER and for PR by immunohistochemistry (IHC). HER2-negative, as defined by ASCO/CAP guidelines) OR II. ER positive (as determined by immunohistochemistry (IHC)) and any of the following high risk characteristics: 1. HER2 positive (IHC or FISH) 2. Node positive 3. Any clinical high-risk expression profile (mammaprint, oncotype, endopredict) 4. PR negative (IHC) OR III. HER 2 positive (as defined by ASCO/ACP guidelines) f. Demonstrates adequate organ function as defined in table below. All screening labs to be obtained within 30 days prior to registration. System Laboratory Value Hematological Leukocytes ≥3,000/mm3 Platelet count ≥ 100,000/mm3 Absolute Neutrophil Count (ANC) ≥ 1,500/mm3 Hemoglobin (Hgb) ≥ 9.0 g/dL Renal Creatinine/Calculated creatinine clearance (CrCl) Cr \< 1.5 x upper limit of normal (ULN) or CrCl ≥ 50 mL/min using the Cockcroft-Gault formula Hepatic Bilirubin Bilirubin ≤ 1.5 × ULN. Subjects with Gilbert's syndrome may have a bilirubin \> 1.5 × ULN, if no evidence of biliary obstruction exists Aspartate aminotransferase (AST) ≤ 2.5 × ULN Alanine aminotransferase (ALT) ≤ 2.5 × ULN g. No evidence of distant metastases (M0 per AJCC staging guidelines) h. Provided written informed consent and HIPAA authorization for release of personal health information, via an approved UIC Institutional Review Board (IRB) informed consent form and HIPAA authorization. i. Women of childbearing potential must not be pregnant or breast-feeding. A negative serum or urine pregnancy test is required per institutional practice guidelines. j. As determined at the discretion of the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study. Exclusion Criteria: 1. Previous anti-cancer treatment (cytotoxic chemotherapy, immunotherapy, biologic therapy, radiotherapy directed towards the primary breast tumor and/or ipsilateral axillary lymph nodes or investigational agents) with therapeutic intent for the current breast cancer. 2. Any type of breast implants 3. Active infection requiring systemic therapy 4. Uncontrolled HIV/AIDS or active viral hepatitis 5. Pregnant or nursing 6. Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of this investigational regimen, as determined by the treating medical oncologist. 7. Any mental or medical condition that prevents the patient from giving informed consent or participating in the trial unless a Legal Authorized Representative (LAR) is in place to sign on behalf of the patient. 8. Other major comorbidity, as determined by study PI
Conditions Diabetes type2
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this project is to improve life of patients with type 2 diabetes through an IT-supported lifestyle and treatment intervention. The intervention is based on combining and adapting existing and effective elements into the IT system of the general practitioner. In this way we will integrate specialist supervised treatment in general practice, individual patient coaching, and improved information exchange and data mining. The DICTA intervention consists of two integrated components: a patient-directed eHealth lifestyle coaching program delivered via the LIVA application, and a clinician-directed CDS tool embedded into the EPJ system. 1. eHealth lifestyle coaching: Individuals with T2D in the intervention group will receive individualized digital coaching from a health coach through the LIVA application. PROs are shared with GPs and health staff via the EPJ, enabling tailored, data-driven lifestyle support. 2. CDS: GPs receive real-time, individualized, algorithm-based pharmacological treatment recommendations for managing T2D, hypertension, and hypercholesterolemia, as appropriate. This is expected to facilitate use, assure individually tailored solutions, optimize treatment effects, and strengthen patient engagement. The study is a randomized controlled trial (RCT). It will include 400 patients with newly diagnosed type 2 diabetes. The patients will receive either treatment based on the intervention or usual care. After one year, we will assess quality of life and cardiovascular risk factors in both groups and evaluate if one group has improved management of their type 2 diabetes compared to the other. If the intervention proves effective, implementation on a national scale is highly feasible, and the intervention could probably be adapted to other lifestyle-related chronic diseases in Denmark and in other countries.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Clinical decision support — Based on the phenotyping and algorithms developed by the hospital specialists at Odense University Hospital and Holbæk Hospital in collaboration with GPs, the individual GPs and their patients will receive individualized recommendations on lifestyle interventions and pharmacological treatments. The GPs will receive specific clinical decision support (CDS) recommendations on what drugs to prescribe to each patient based on the phenotyping in accordance with a clinical decision support tool (Cambio) and the updated guidelines at all times (Sparrow 2019). The treatment advice to the GPs will be adjusted annually based on treatment effect, re-phenotyping, and updated knowledge of the treatment of T2D. Furthermore, psychiatric, socioeconomic and/or cultural challenges and other determinants for frailty will be a part of the individualized intervention provided to patients by the GPs, again based on the specialist advice.
  • Behavioral: Digital Lifestyle Coaching — As part of DICTA, the patients are offered a personal health coach (dietician, nurse, occupational therapist, or physiotherapist) through the complex eHealth intervention (Liva). Patients will receive personalized empathic, relation driven coaching on healthy lifestyle on the individual patient's preferences (e.g. increased physical activity, healthier diet, weight loss, smoking cessation, personal goal setting, tailored information, peer to peer support), including optimal pharmacological treatment (Komkova 2019). The collaborative eHealth tool will give health coaches access to patient registered outcome measurements (PRO), information. This forms the basis of the individual coaching and is partly supported by artificial intelligence (AI) to improve the coaching by the health coaches (Holzinger 2016).
  • Behavioral: Integration to Standard Electronic Health Record — Data on physical activity, steps, diet goal fulfillment, smoking status etc., are being provided for GPs in a web-based solution integrated into the GPs' health record system. Integration with the GP system XMO (covering 52% of all Danish GPs) has been finalized.

Primary Outcomes

  • Change in a binary indicator, composed by a composite endpoint of HbA1c, systolic blood pressure, low-density lipoprotein cholesterol, no smoking, and normal albuminuria (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-06-01
Completion: 2025-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern Denmark
Collaborators: Steno Diabetes Center Odense, Odense University Hospital, Steno Diabetes Center Sjaelland, Aalborg University, Holbaek Sygehus, Slagelse Sygehus
Principal Investigators:
  • Jens H Søndergaard (PRINCIPAL_INVESTIGATOR) - University of Southern Denmark
Contact Information
Study Contact:
Carl J Brandt, PhD
+45 2014 1566
cbrandt@health.sdu.dk
Michael Olesen, Prof.
+45 6550 3830
michael.olsen@dadlnet.dk
Carl J Brandt, MD
+45 2014 1566
cbrandt@health.sdu.dk
Research Unit for General Practice, Department for Public Health, University of Southern Denmark
Interventions
  • Behavioral: Clinical decision support — Based on the phenotyping and algorithms developed by the hospital specialists at Odense University Hospital and Holbæk Hospital in collaboration with GPs, the individual GPs and their patients will receive individualized recommendations on lifestyle interventions and pharmacological treatments. The GPs will receive specific clinical decision support (CDS) recommendations on what drugs to prescribe to each patient based on the phenotyping in accordance with a clinical decision support tool (Cambio) and the updated guidelines at all times (Sparrow 2019). The treatment advice to the GPs will be adjusted annually based on treatment effect, re-phenotyping, and updated knowledge of the treatment of T2D. Furthermore, psychiatric, socioeconomic and/or cultural challenges and other determinants for frailty will be a part of the individualized intervention provided to patients by the GPs, again based on the specialist advice.
  • Behavioral: Digital Lifestyle Coaching — As part of DICTA, the patients are offered a personal health coach (dietician, nurse, occupational therapist, or physiotherapist) through the complex eHealth intervention (Liva). Patients will receive personalized empathic, relation driven coaching on healthy lifestyle on the individual patient's preferences (e.g. increased physical activity, healthier diet, weight loss, smoking cessation, personal goal setting, tailored information, peer to peer support), including optimal pharmacological treatment (Komkova 2019). The collaborative eHealth tool will give health coaches access to patient registered outcome measurements (PRO), information. This forms the basis of the individual coaching and is partly supported by artificial intelligence (AI) to improve the coaching by the health coaches (Holzinger 2016).
  • Behavioral: Integration to Standard Electronic Health Record — Data on physical activity, steps, diet goal fulfillment, smoking status etc., are being provided for GPs in a web-based solution integrated into the GPs' health record system. Integration with the GP system XMO (covering 52% of all Danish GPs) has been finalized.
Study Locations (1 sites)
Research Unit for General Practice, Department for Public Health, University of Southern Denmark, Odense, Region Syddanmark Denmark
Eligibility Criteria
Inclusion Criteria: * Diabetes type 2 in up to 10 years Exclusion Criteria: * Fails to complete the initial questionnaire * No Internet access in own home through computer or smart phone * Is pregnant or actively trying to get pregnant * Has a serious or life-threatening disease
Conditions Diabetes Mellitus, Type 2, Overweight an...
Phase NA
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

In this project, the investigators will perform a multicenter randomised controlled trial to determine whether advice to consume a moderate, whole food-based low-carbohydrate high-fat (LCHF) ad libitum diet (CarbCount program) can produce and maintain equal remission rates of type 2 diabetes (T2D) as a nutritionally complete very-low-calorie formula diet followed by a energy-restrictive (i.e., calorie counting) diet (DiRECT principles). Within the principles of each approach, the dietary goals and change will be adjusted according to individual needs/capabilities conducive to long-term adherence. Furthermore, the investigators aim to determine whether the rate of diet-induced remission is reflected in/can be predicted by baseline or diet-induced changes in glucose variability (e.g., time-in-range measured by continuous glucose monitoring) and other factors such as anthropometric changes and genetic susceptibility. Each center will also conduct locally-lead standalone mechanistic research, including analyses of intra-abdominal/hepatic fat accumulation, adipose tissue biopsies and/or measurements of energy metabolism. Additionally, changes in medication use, nutritional status, cardiovascular disease risk, as well as adverse events, will be monitored.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: Energy restricted diet — Nutritional complete formula diet followed by an energy restricted diet
  • Other: Low carbohydrate high fat diet — Very low-carbohydrate high-fat ketogenic diet (VLCHF) diet followed by a low-carbohydrate high-fat diet (LCHF)

Primary Outcomes

  • Diabetes remission (15 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2022-01-04
Completion: 2040-12-31
Eligibility
Age: 24 Years and older
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Bergen
Collaborators: Karolinska Institutet, University of Glasgow, University of Copenhagen, Technical University of Munich
Contact Information
Study Contact:
Simon N Dankel, PhD
+4794308637
Simon.Dankel@uib.no
Kristin Amundsen, MSc
+4797171257
k.amundsen@uib.no
Pål R Njølstad
+47 55 97 51 53
Pal.Njolstad@uib.no
Department of Clinical Science
Interventions
  • Other: Energy restricted diet — Nutritional complete formula diet followed by an energy restricted diet
  • Other: Low carbohydrate high fat diet — Very low-carbohydrate high-fat ketogenic diet (VLCHF) diet followed by a low-carbohydrate high-fat diet (LCHF)
Study Locations (1 sites)
Department of Clinical Science, Bergen, Vestland 5021 Norway
Eligibility Criteria
Inclusion Criteria: * HbA1c ≥48 mmol/mol (with or without medical treatment) * Less than 10 years since the diagnosis of T2D * BMI ≥27 kg/m2 (≥25 kg/m2 for Asians) Exclusion Criteria: * Treatment with insulin \>25 IU * HbA1c concentration of 12% or more (≥108 mmol/mol) * Insulin to C-peptide ratio \<0.8 (indicative of insulin deficiency) * Myocardial infarction within the previous 6 months, and severe or unstable heart failure or other severe diseases including cancer, psychiatric/eating disorders, severe depression and substance abuse
Conditions Stage I Breast Cancer
Phase PHASE3
Enrollment 1670
Locations 832 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) — Post lumpectomy radiation therapy will be external beam radiation to either the whole breast + boost, partial breast irradiation, or Accelerated Partial Breast Irradiation that must begin within 12 weeks of the last breast cancer surgery(including re-excision of margins). Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s). Endocrine therapy may be initiated before, during, or after completion of radiation therapy at the discretion of the investigator.
  • Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) — Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s).

Primary Outcomes

  • Time to invasive or noninvasive IBTR. (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2021-06-23
Completion: 2041-07
Eligibility
Age: 50 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1670 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NRG Oncology
Collaborators: National Cancer Institute (NCI)
Contact Information
Study Contact:
Director Department of Regulatory Affairs
412-339-5300
langerj@nrgoncology.org
Norman Wolmark, MD
Site Public Contact
251-445-9870
pfrancisco@usouthal.edu
University of South Alabama Mitchell Cancer Institute
Interventions
  • Other: Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) — Post lumpectomy radiation therapy will be external beam radiation to either the whole breast + boost, partial breast irradiation, or Accelerated Partial Breast Irradiation that must begin within 12 weeks of the last breast cancer surgery(including re-excision of margins). Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s). Endocrine therapy may be initiated before, during, or after completion of radiation therapy at the discretion of the investigator.
  • Drug: Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane) — Endocrine therapy for a minimum of 5 years. The specific regimen of endocrine therapy is at the treating physician's discretion. The dose and schedule of the drug(s) used for endocrine therapy should be consistent with the instructions in the drug package insert(s).
Study Locations (832 sites)
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama 35233 United States
University of South Alabama Mitchell Cancer Institute, Mobile, Alabama 36688 United States
Kingman Regional Medical Center, Kingman, Arizona 86401 United States
Cancer Center at Saint Joseph's, Phoenix, Arizona 85004 United States
Mayo Clinic Hospital in Arizona, Phoenix, Arizona 85054 United States
University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205 United States
Kaiser Permanente-Anaheim, Anaheim, California 92806 United States
Kaiser Permanente-Deer Valley Medical Center, Antioch, California 94531 United States
Mission Hope Medical Oncology - Arroyo Grande, Arroyo Grande, California 93420 United States
PCR Oncology, Arroyo Grande, California 93420 United States
Eligibility Criteria
Inclusion Criteria: * • The patient or a legally authorized representative must provide study-specific informed consent prior to pre-entry/Step 1 and, for patients treated in the U.S., authorization permitting release of personal health information. * The patient must have an ECOG performance status of 0 or 1. * The patient must have undergone a lumpectomy and the margins of the resected specimen or re-excision must be histologically free of invasive tumor and DCIS with no ink on tumor as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins. (Patients with margins positive for LCIS are eligible without additional resection.) * The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination. * Patient must have undergone axillary staging (sentinel node biopsy and/or axillary node dissection). * The following staging criteria must be met postoperatively according to AJCC 8th edition criteria: * By pathologic evaluation, primary tumor must be pT1 (less than or equal to 2 cm). * By pathologic evaluation, ipsilateral nodes must be pN0. (Patients with pathologic staging of pN0(i+) or pN0(mol+) are NOT eligible.) * Oncotype DX Recurrence Score of less than or equal to 18 on diagnostic core biopsy or resected specimen. \*\* For patients with a T1a tumor (less than or equal to 0.5 cm in size) or patients at Canadian provinces or approved international sites where Oncotype DX Recurrence Score testing would not be covered, who do not already have an Oncotype DX Recurrence Score at pre-entry/Step 1, a specimen (unstained blocks or slides) must be sent to the Genomic Health centralized laboratory. Tumor size sample must be greater than or equal to 0.2 cm for analysis. \*\*\* The Oncotype RS can be run on the biopsy core or surgical specimen. The patient cannot have initiated endocrine therapy prior to tissue collection. * An Oncotype RS is required for eligibility, however, for a patient whose tumor has already had a MammaPrint test completed as part of usual care when being considered for enrollment and is in the binary "Low" category will meet this eligibility criteria and an Oncotype RS does not need to be performed. * The tumor must have been determined to be ER and/or PgR positive assessed by current ASCO/CAP Guideline Recommendations for hormone receptor testing. Patients with greater than or equal to 1% ER or PgR staining by IHC are considered positive. * The tumor must have been determined to be HER2-negative by current ASCO/CAP guidelines. * Patients may be premenopausal or postmenopausal at the time of pre-entry/Step 1. For study purposes, postmenopausal is defined as: * Age 56 or older with no spontaneous menses for at least 12 months prior to pre-entry/Step 1; or a documented hysterectomy; or * Age 55 or younger with no spontaneous menses for at least 12 months prior to pre-entry/Step 1 (e.g., spontaneous or secondary to hysterectomy) and with a documented estradiol level in the postmenopausal range according to local institutional/laboratory standard; or Documented bilateral oophorectomy. * The interval between the last surgery for breast cancer (including re-excision of margins) and pre-entry/Step 1 must be no more than 70 days. * The patient must have recovered from surgery with the incision completely healed and no signs of infection. * Bilateral mammogram or MRI within 6 months prior to pre-entry/Step 1. HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Patients must be intending to take endocrine therapy for a minimum 5 years duration (tamoxifen or aromatase inhibitor). The specific regimen of endocrine therapy is at the treating physician's discretion. Exclusion Criteria: * • Definitive clinical or radiologic evidence of metastatic disease. * pT1 mi and pT2 - pT4 tumors including inflammatory breast cancer. * Pathologic staging of pN0(i+) or pN0(mol+), pN1, pN2, or pN3 disease. * Patient had a mastectomy. * Palpable or radiographically suspicious ipsilateral or contralateral axillary, supraclavicular, infraclavicular, or internal mammary nodes, unless there is histologic confirmation that these nodes are negative for tumor. * Suspicious microcalcifications, densities, or palpable abnormalities (in the ipsilateral or contralateral breast) unless biopsied and found to be benign. * Non-epithelial breast malignancies such as sarcoma or lymphoma. * Proven multicentric carcinoma (invasive cancer or DCIS) in more than one quadrant or separated by 4 or more centimeters. (Patients with multifocal carcinoma are eligible.) * Paget's disease of the nipple. * Any history, not including the index cancer, of ipsilateral invasive breast cancer or ipsilateral DCIS treated or not treated. (Patients with synchronous or previous ipsilateral LCIS are eligible.) * Synchronous or previous contralateral invasive breast cancer or DCIS. (Patients with synchronous and/or previous contralateral LCIS are eligible.) * Surgical margins that cannot be microscopically assessed or are positive at pathologic evaluation. (If surgical margins are rendered free of disease by re- excision, the patient is eligible.) * Treatment plan that includes regional nodal irradiation. * Any treatment with radiation therapy, chemotherapy, or biotherapy, administered for the currently diagnosed breast cancer prior to pre-entry/Step 1. * History of non-breast malignancies (except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin) within 5 years prior to pre-entry/Step 1. * Current therapy with any endocrine therapy such as raloxifene (Evista®), tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or breast cancer prevention. \*\* Patients are eligible for BR007 if they receive a short course of preoperative endocrine therapy of less than 6 weeks duration (prior to randomization/Step 2) for this diagnosis after the core biopsy (and can continue postoperatively if: * the Oncotype DX Recurrence Score is assessed on the biopsy core and is less than or equal to 18, AND * the patient had not initiated endocrine therapy prior to core biopsy tissue collection. \*\*\* This does not apply to adjuvant endocrine therapy recommended for this diagnosis which may start any time after surgery including prior to registration (Pre-entry/Step 1). * Patients intending to continue on oral, transdermal, or subdermal estrogen replacement (including all estrogen only and estrogen-progesterone formulas) are not eligible. Patients that discontinue oral, transdermal, or subdermal estrogen replacement prior to registration are eligible. * Prior breast or thoracic RT for any condition. * Active collagen vascular disease, specifically dermatomyositis with a CPK level above normal or with an active skin rash, systemic lupus erythematosis, or scleroderma. * Pregnancy or lactation at the time of pre-entry/Step 1 or intention to become pregnant during treatment. (Note: Pregnancy testing according to institutional standards for women of childbearing potential must be performed within 2 weeks prior to pre-entry/Step 1.) * Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of study therapy or that may affect the interpretation of the results or render the patient at high risk from treatment complications. * Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements or interfere with interpretation of study results. * Use of any investigational product within 30 days prior to p

Brief Smartphone Treatment Study

NCT04846777
Recruiting
Conditions Generalized Anxiety Disorder
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Little is known about whether and how brief mindfulness therapies yield clinically beneficial effects. This gap exists despite the rapid growth of smartphone mindfulness applications and presence of mental health treatment gap. Specifically, no prior brief, smartphone mindfulness ecological momentary intervention (MEMI) has targeted generalized anxiety disorder (GAD). Moreover, although theories propose that mindfulness intervention can boost attentional control (AC), executive functioning (EF), perspective-taking, and social cognition skills they have largely gone untested. Thus, this randomized controlled trial (RCT) aims to address these gaps by assessing the efficacy of a 14-day smartphone mindfulness EMI (vs. placebo). Participants with GAD will be randomly assigned to either MEMI or self-monitoring placebo (SMP). Those in treatment will exercise multiple core mindfulness strategies (open monitoring, acceptance, attending to small moments, slowed rhythmic diaphragmatic breathing). Also, those in MEMI will be reminded before bedtime that mindfulness is a lifelong practice. Comparatively, participants assigned to SMP will only be prompted to practice self-monitoring. They will notice their thoughts, rate any distress associated with them, and will not be taught any mindfulness strategies. All prompts will occur 5 times a day, for 14 consecutive days. They will complete self-reports and neuropsychological assessments at pre-, post-, and 1-month follow-up. Multilevel modeling analyses will determine if treatment (vs. self-monitoring placebo (SMP)) produces substantially larger reductions in trait worry and negative perseverative cognitions as well as steeper increases in AC and EF (inhibition, set-shifting, working memory updating). In addition, the investigators hypothesized that MEMI (vs. SMP) would lead to greater increases in performance-based and self-reported trait mindfulness, empathy, and perspective taking. Findings will advance understanding of the efficacy of unguided, technology-assisted, brief mindfulness in a clinical sample.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Device: Mindfulness ecological momentary intervention — Access to a smartphone-delivered mindfulness ecological momentary intervention with the Personal Analytics Companion (PACO) app that regularly prompts participants to practice various mindfulness skills at 5 preset times each day.
  • Device: Self-monitoring placebo — Access to a smartphone-delivered self-monitoring placebo with the PACO app that regularly prompts participants to practice self-monitoring at 5 preset times each day.

Primary Outcomes

  • Change from Baseline Generalized Anxiety Disorder Symptoms at 14-Day Post-Treatment (Baseline to 14-Day Post-Treatment)
  • Change from Baseline Generalized Anxiety Disorder Symptoms at 6-Week Post-Randomization (Baseline to 6-Week Post-Randomization)
  • Change from Baseline Perseverative Cognitions at 14-Day Post-Treatment (Baseline to 14-Day Post-Treatment)
  • Change from Baseline Perseverative Cognitions at 6-Week Post-Randomization (Baseline to 6-Week Post-Randomization)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2018-11-14
Completion: 2023-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Penn State University
Principal Investigators:
  • Nur Hani Zainal, M.S. (PRINCIPAL_INVESTIGATOR) - The Pennsylvania State University
Contact Information
Study Contact:
Nur Hani Zainal, M.S.
917-767-7088
nvz5057@psu.edu
Michelle G. Newman, Ph.D.
814-883-4572
mgn1@psu.edu
Nur Hani Zainal, M.S.
917-767-7088
nvz5057@psu.edu
The Pennsylvania State University
Interventions
  • Device: Mindfulness ecological momentary intervention — Access to a smartphone-delivered mindfulness ecological momentary intervention with the Personal Analytics Companion (PACO) app that regularly prompts participants to practice various mindfulness skills at 5 preset times each day.
  • Device: Self-monitoring placebo — Access to a smartphone-delivered self-monitoring placebo with the PACO app that regularly prompts participants to practice self-monitoring at 5 preset times each day.
Study Locations (1 sites)
The Pennsylvania State University, University Park, Pennsylvania 16802 United States
Eligibility Criteria
Inclusion Criteria: * Presence of Generalized Anxiety Disorder based on the Generalized Anxiety Disorder Questionnaire-IV self-report and Mini International Neuropsychiatric Interview * Current student at the Pennsylvania State University or a community-dwelling adult who expressed interest to participate through the PSU StudyFinder portal * Expressed interest to seek treatment * Currently not receiving treatment from a mental health professional * Able to provide consent * Proficient in English Exclusion Criteria: * Below age 18 * Failure to meet any of above inclusion criteria * Participant currently undergoing * Presence of suicidality, mania, psychosis, or substance use disorders